Document:

Agreement, dated as of August 5, 2002

 EXHIBIT 10.10 
  
 AGREEMENT 
  
 This Grant-in-Aid Agreement with Novacea Inc. (hereinafter referred to as “Sponsor”) with an address of 601 Gateway Boulevard, Suite 450, South San Francisco,
California 94080, is the sponsor or sponsor-investigator, as those terms are defined in Title 21 of the Code of Federal Regulations, CFR 312.3, of a study (the “Study”) entitled: 
  
 “A Phase 2/3 Multicenter, Randomized, Double Blind, Study of
Docetaxel Plus DN-101 or Placebo in Androgen-Independent Prostate Cancer (AIPC)”; and 
  
 WHEREAS, Aventis Pharmaceuticals Inc. (“AVENTIS”), has an interest in the results and findings of the Study, which it has not sponsored; 
  
 NOW, THEREFORE, AVENTIS and Sponsor, for valuable consideration and intending to be legally bound, agree as follows. 
  

	1.	Upon confirmation to AVENTIS of Sponsor’s receipt of all required authorizations to conduct the Study as outlined in Exhibit A, incorporated by reference and made part of this
Agreement hereto, in accordance with applicable law, AVENTIS shall provide to Sponsor Grant-in-Aid Study funds as described in Paragraph 4 below. 

  

	2.	Sponsor shall: 

  

	 	a.	Use such funds supplied by AVENTIS pursuant to this Agreement only for carrying out the Study. 

  

	 	b.	Conduct the Study according to the protocol that Sponsor has submitted to AVENTIS for review. Sponsor shall assume responsibility for billing investigational subjects and third
parties for services furnished pursuant to an approved protocol, only as permitted by applicable law. 

  

	 	c.	Conduct the Study in accordance with all applicable federal, state and local laws and regulations, including without limitation FDA regulations and guidelines for good clinical
practices, and all written instructions from AVENTIS regarding the Study medication. 

  

	 	d.	Furnish AVENTIS with copies of Study documents upon request, provide information regarding Study progress, including written quarterly reports if requested, and allow AVENTIS access
to any and all Study data upon request. Reports to AVENTIS will not use subjects’ names without subjects’ consent. Absent consent, a numerical system will be used to protect each subject’s confidentiality. In the event that any
subjects’ names are inadvertently divulged, AVENTIS will delete the identifying information. It shall be Sponsor’s responsibility to ensure that all requirements regarding confidentiality are satisfied. 

  

	 	e.	 Report all adverse experiences directly to the FDA and/or the applicable AVENTIS clinical team in accordance with applicable law and Study protocol, 

 
with a copy of any FDA reports sent directly to AVENTIS. A copy of all serious, related adverse event reports will be forwarded to AVENTIS Global
Pharmacovigilance and Epidemiology (Email: GPEmailbox@aventis.com; Fax: 908-231-4827) within 24 hours ‘of receipt by Sponsor. 
  

	 	f.	Provide AVENTIS with a final report of Study results upon completion of Study. 

  

	 	g.	Submit an advance copy of any publication for review and comment to AVENTIS thirty (30) days prior to the planned publication date. Upon written request by AVENTIS to Sponsor
within such thirty (30) days, Sponsor agrees to delay such publication until AVENTIS determines that the publication will not compromise any patent rights. However, such delay shall not exceed ninety (90) additional days.

  

	 	h.	Return to AVENTIS all unearned funds not substantiated by Study expenses. 

  

	3.	AVENTIS shall provide Sponsor Grant-in-Aid funds for the conduct of the Study in the total amount of Two-Million Nine-Hundred Sixty-Nine Thousand, Five-Hundred Twenty-Three Dollars
($2,969,523), to be paid as outlined in Exhibit B. 

  

					
	4.	    	Payment shall be made to:	 	Novacea Inc.
	 	    	 	 	Attn.: Brad Goodwin, CEO
	 	    	 	 	601 Gateway Boulevard
	 	    	 	 	Suite 450
	 	    	 	 	South San Francisco, California 94080
	 	    	 	 	Federal Tax ID No.: 33-0960223

  

	5.	For all purposes herein, “Invention” shall mean any discovery, improvement, concept or idea whether or not patentable or copyrightable, which (i) arises out of work
performed pursuant to the obligations of this Agreement; (ii) is conceived during the term of the Agreement; and (iii) includes but is not limited to processes, methods, software, formulae, techniques, compositions of matter, devices, and
improvements thereof and know-how relating thereto. Sponsor will disclose promptly to AVENTIS or its nominee any and all Inventions, patentable or not, arising out of work pursuant to use of Confidential Information (as identified in paragraph 7
below) and all such Inventions shall be jointly owned by AVENTIS and the Sponsor. Any Joint Invention relating solely to the manufacture, use or sale of Taxotere may be sublicensed by Novacea only with the prior consent of Aventis, which consent
shall not be unreasonably withheld. Any Joint Invention relating solely to the manufacture, use or sale of Vitamin D or any analog or derivative of Vitamin D may be sublicensed by Aventis only with the prior consent of Novacea, which consent shall
not be unreasonably withheld. The parties shall in good faith cooperate in obtaining, maintaining and defending any intellectual property rights, both U.S. and foreign, to Invention. These obligations shall continue beyond the termination of this
Agreement with respect to Inventions, discoveries and improvements conceived or made during the course of or as a result of the work to be done pursuant to this Agreement. 

	6.	All materials, documents and information supplied by one party to the other pursuant to this Agreement are the Confidential Information of the disclosing party and may be used by
the receiving party only to the extent necessary to perform its obligations hereunder. The receiving party will not disclose any Confidential Information of the other party without the prior written consent of the disclosing party, other than to the
FDA, hospital authorities, MB members, and clinical investigators, and to the agents and employees of the receiving party on a need-to-know basis. The obligations of the receiving party under this paragraph 7 shall continue in effect for a period of
10 years from the effective date of this Agreement. The foregoing obligations regarding the confidentiality and nondisclosure of information shall not apply to information that: 

  

	 	a.	is already known to receiving party at the time of disclosure hereunder; 

  

	 	b.	is or becomes publicly available through no fault of receiving party or anyone doing work under their direction pursuant to the terms of this Agreement; 

  

	 	c.	is received from a third party that receiving party believes in good faith has a right to disclose it; or 

  

	 	d.	is required by law to be disclosed. 

  

	7.	Sponsor agrees to provide, and Sponsor agrees to cause all investigators and sub-investigators to provide, AVENTIS with such information as AVENTIS shall request from time to time
regarding direct or indirect financial interests or other arrangements between Sponsor and/or Aventis and any individual who will be directly involved in the treatment or evaluation of research subjects participating in the Study, all in accordance
with the requirements of 21 CFR 54. 

  

	8.	For the purposes of this Agreement the term “AVENTIS” shall be deemed to include Aventis Pharmaceuticals Inc. and its affiliates. 

  

	9.	This Agreement shall be governed by the laws of the State of New Jersey. 

  

	10.	This Agreement constitutes the entire Agreement between the parties regarding the subject matter hereof and may be changed or modified only by an instrument in writing that is
signed by the parties. 

  

							
	 AVENTIS PHARMACEUTICALS INC.
	  	 	  	 
				
	 By
	 	 /s/ Michael S. Boyer

	  	Date 8/5/02	  	 
	 	 	 Michael S. Boyer, RPh, MSc
	  	 	  	 
	 	 	 Director, Clinical Oncology Programs
	  	 	  	 

							
	 By
	 	 /s/ Hervé J. Hoppenot

	  	Date 8/5/02	  	 
	 	 	 Hervé J. Hoppenot
	  	 	  	 
	 	 	 VP, US Oncology Operations
	  	 	  	 
			
	 NOVACEA INC.
	  	 	  	 
				
	 By
	 	 /s/ Brad Goodwin

	  	Date 7/31/02	  	 
	Name	 	Brad Goodwin	  	 	  	 
	Title	 	Chief Executive Officer	  	 	  	 

 EXHIBIT B 
  

A Phase 2/3 Multicenter, Randomized, Double Blind, Study of Docetaxel Plus 
 DN-101 or Placebo in Androgen-Independent Prostate Cancer (AIPC) 
 (GIA #16106)

  
 Novacea Inc. 
  
 Payment Schedule 
  

									
	Payment

	  	%

	 	 	 Milestone

	  	Amount

	1	  	12.5	%	 	 After signed contract and all required documents (approved protocol, IRB approval, IND documentation) have been received by
Aventis
	  	$	371,190.37
				
	2	  	8.3	%	 	 After receipt of documentation of first 25 patients accrued and all reported SAEs (Fax cover sheet and copy of MedWatch form
only)
	  	$	247,460.25
				
	3	  	8.3	%	 	 After receipt and review of Interim Report for 50 patients and all reported SAEs (Fax cover sheet and copy of MedWatch forms not previously
submitted)
	  	$	247,460.25
				
	4	  	83	%	 	 After receipt of documentation of first 75 patients accrued and all reported SAEs (Fax cover sheet and copy of MedWatch form
only)
	  	$	247,460.25
				
	5	  	8.3	%	 	 After receipt and review of Interim Report for 100 patients and all reported SAEs (Fax cover sheet and copy of MedWatch forms not
previously submitted)
	  	$	247,460.25
				
	6	  	8.3	%	 	 After receipt of documentation of first 125 patients accrued and all reported SAEs (Fax cover sheet and copy of MedWatch form
only)
	  	$	247,460.25
				
	7	  	8.3	%	 	 After receipt and review of Interim Report for 150 patients and all reported SAEs (Fax cover sheet and copy of MedWatch forms not
previously submitted)
	  	$	247,460.25
				
	8	  	83	%	 	 After receipt of documentation of first 175 patients accrued and all reported SAEs (Fax cover sheet and copy of MedWatch form
only)
	  	$	247,460.25
				
	9	  	8.3	%	 	 After receipt and review of Interim Report for 200 patients and all reported SAEs (Fax cover sheet and copy of MedWatch forms not
previously submitted)
	  	$	247,46025
				
	10	  	8.3	%	 	 After receipt of documentation of 100% accrual (232 patients)* and all reported SAEs (Fax cover sheet and copy of MedWatch forms not
previously submitted)
	  	$	247,460.25
				
	Final	  	12.5	%	 	 Thirty (30) days after receipt of Final Study Report or Manuscript by Aventis
	  	$	371,190.37
	 	  	 	 	 	 	  	
	

	Total	  	100	%	 	 	  	$	2,969,523
	 	  	 	 	 	 	  	
	

	*	Payment based on actual number of patients accrued to study. 

  

 Page 1 of 1Agreement, dated as of August 4, 2003

 EXHIBIT 10.11 
  
 AGREEMENT 
  
 This Agreement with Novacea Inc. (hereinafter referred to as “Sponsor”) with an address of 601 Gateway Boulevard, Suite 450, South San Francisco, California
94080, is the sponsor or sponsor-investigator, as those terms are defined in Title 21 of the Code of Federal Regulations, CFR 312.3, of a study (the “Study”) entitled: 
  
 “A Phase 1 / 2 Multicenter, Open Label, Dose Ranging Study of DN-101 and Taxotere® in Patients with Advanced
(Stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) who Have Failed Previous Therapy with Platinum-Based Chemotherapy”; and 
  
 WHEREAS, Aventis Pharmaceuticals Inc. (“AVENTIS”), has an interest in the results and findings of the Study, which it has not sponsored; 
  
 NOW, THEREFORE, AVENTIS and Sponsor, for valuable
consideration and intending to be legally bound, agree as follows. 
  

	1.	Upon confirmation to AVENTIS of Sponsor’s receipt of all required authorizations to conduct the Study in accordance with applicable law, AVENTIS shall provide to Sponsor
Grant-in-Aid Study funds as described in Paragraph 4 below. 

  

	2.	Sponsor shall: 

  

	 	a.	Use such funds supplied by AVENTIS pursuant to this Agreement only for carrying out the Study. 

  

	 	b.	Conduct the Study according to the protocol that Sponsor has submitted to AVENTIS for review. Sponsor shall assume responsibility for billing investigational subjects and third
parties for services furnished pursuant to an approved protocol, only as permitted by applicable law. 

  

	 	c.	Conduct the Study in accordance with all applicable federal, state and local laws and regulations, including without limitation FDA regulations and guidelines for good clinical
practices, and all written instructions from AVENTIS regarding the Study medication. 

  

	 	d.	Furnish AVENTIS with copies of Study documents upon request, provide information regarding Study progress, including written quarterly reports if requested, and allow AVENTIS access
to any and all Study data upon request. Reports to AVENTIS will not use subjects’ names without subjects’ consent. Absent consent, a numerical system will be used to protect each subject’s confidentiality. In the event that any
subjects’ names are inadvertently divulged, AVENTIS will delete the identifying information. It shall be Sponsor’s responsibility to ensure that all requirements regarding confidentiality are satisfied. 

  

	 	e.	 Report all adverse experiences directly to the FDA and/or the applicable AVENTIS clinical team in accordance with applicable law and Study protocol, 

 
with a copy of any FDA reports sent directly to AVENTIS. A copy of all serious, related adverse event reports will be forwarded to AVENTIS Global
Pharmacovigilance and Epidemiology (Email: GPEmailbox@aventis.com; Fax: 908-231-4827) within 24 hours of receipt by Sponsor. 
  

	 	f.	Provide AVENTIS with a final report of Study results upon completion of Study. 

  

	 	g.	Submit to AVENTIS for review, for editorial and patent protection purposes, any manuscript or abstract prepared for publication at least 30 days prior to submission to publisher.
Upon written request by AVENTIS to Sponsor within such thirty (30) days, Sponsor agrees to delay such publication until AVENTIS determines that the publication will not compromise any patent rights. However, such delay shall not exceed ninety
(90) additional days. 

  

	 	h.	Return to AVENTIS all unearned funds not substantiated by Study expenses. 

  

	3.	AVENTIS shall provide Sponsor funds for the conduct of the Study in the total amount of Three hundred and seventy two thousand dollars ($372,000.00), to be paid as outlined in
Exhibit B. 

  

					
	4.	    	Payment shall be made to:	 	Novacea Inc.
	 	    	 	 	Attn.: Brad Goodwin, CEO
	 	    	 	 	601 Gateway Boulevard
	 	    	 	 	Suite 450
	 	    	 	 	South San Francisco, California 94080
	 	    	 	 	Federal Tax ID No.: 33-0960223

  

	5.	For all purposes herein, “Invention” shall mean any discovery, improvement, concept or idea whether or not patentable or copyrightable, which (i) arises out of work
performed pursuant to the obligations of this Agreement; (ii) is conceived during the term of the Agreement; and (iii) includes but is not limited to processes, methods, software, formulae, techniques, compositions of matter, devices, and
improvements thereof and know-how relating thereto. Sponsor will disclose promptly to AVENTIS or its nominee any and all Inventions, patentable or not, arising out, of work pursuant to use of Confidential Information (as identified in paragraph 7
below) and all such Inventions shall be jointly owned by AVENTIS and the Sponsor. Any Joint Invention relating solely to the manufacture, use or sale of Taxotere may be sublicensed by Novacea only with the prior consent of Aventis, which consent
shall not be unreasonably withheld. Any Joint Invention relating solely to the manufacture, use or sale of Vitamin D or any analog or derivative of Vitamin D may be sublicensed by Aventis only with the prior consent of Novacea, which consent shall
not be unreasonably withheld. The parties shall in good faith cooperate in obtaining, maintaining and defending any intellectual property rights, both U.S. and foreign, to Invention. These obligations shall continue beyond the termination of this
Agreement with respect to Inventions, discoveries and improvements conceived or made during the course of or as a result of the work to be done pursuant to this Agreement. 

	6.	All materials, documents and information supplied by one party to the other pursuant to this Agreement are the Confidential Information of the disclosing party and may be used by
the receiving party only to the extent necessary to perform its obligations hereunder. The receiving party will not disclose any Confidential Information of the other party without the prior written consent of the disclosing party, other than to the
FDA, hospital authorities, IRB members, and clinical investigators, and to the agents and employees of the receiving party on a need-to-know basis. The obligations of the receiving party under this paragraph 7 shall continue in effect for a period
of 10 years from the effective date of this Agreement. The foregoing obligations regarding the confidentiality and nondisclosure of information shall not apply to information that: 

  

	 	a.	is already known to receiving party at the time of disclosure hereunder; 

  

	 	b.	is or becomes publicly available through no fault of receiving party or anyone doing work under their direction pursuant to the terms of this Agreement; 

  

	 	c.	is received from a third party that receiving party believes in good faith has a right to disclose it; or 

  

	 	d.	is required by law to be disclosed. 

  

	7.	Sponsor agrees to provide, and Sponsor agrees to cause all investigators and sub-investigators to provide, AVENTIS with such information as AVENTIS shall request from time to time
regarding direct or indirect financial interests or other arrangements between Sponsor and/or Aventis and any individual who will be directly involved in the treatment or evaluation of research subjects participating in the Study, all in accordance
with the requirements of 21 CFR 54. 

  

	8.	For the purposes of this Agreement the term “AVENTIS” shall be deemed to include Aventis Pharmaceuticals Inc. and its affiliates. 

  

	9.	This Agreement shall be governed by the laws of the State of New Jersey. 

  

	10.	This Agreement constitutes the entire Agreement between the parties regarding the subject matter hereof and may be changed or modified only by an instrument in writing that is
signed by the parties. 

  
 The parties hereto have
caused this Agreement to be executed as of the date indicated below. 
  

							
	 AVENTIS PHARMACEUTICALS INC.
	  	 	  	 
				
	 By
	 	 /s/ Michael S. Boyer

	  	Date 8/4/03	  	 
	 	 	 Michael S. Boyer, RPh, MSc
	  	 	  	 
	 	 	 Director, Clinical Oncology Programs
	  	 	  	 

							
	NOVACEA INC.	  	 	  	 
				
	By	 	 /s/ Brad Goodwin

	  	Date 8/3/03	  	 
	Name	 	Brad Goodwin	  	 	  	 
	Title	 	Chief Executive Officer	  	 	  	 

 EXHIBIT B 
  

A Phase I/II Multicenter, Open-Label, Dose Ranging Study of DN-101 and Taxotere 
 in Patients with Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) 
 Who Have Failed Previous Therapy with Platinum-Based Chemotherapy 
 (IIT #12196) 
  
 Novacea Inc. 
 Payment Schedule 
  

									
	 Phase I:
	  	 	 	 	 	  	 	 
				
	 Payment

	  	Percentage

	 	 	 Milestone

	  	Amount

	 First
	  	25	%	 	 After signed contract and all required documents have been received by Aventis
	  	$	93,000
				
	 Second
	  	10	%	 	 After receipt of documentation of 100% accrual for Phase I portion of study and all reported
SAE’s
 (Fax copy of Medwatch form only)
	  	$	37,200
				
	 Third
	  	15	%	 	 After receipt and review of Interim Report for completed Phase I portion of study and all reported SAE’s (Fax copy of Medwatch forms not
previously submitted)
	  	$	55,800
				
	 Phase II:
	  	 	 	 	 	  	 	 
				
	 Payment

	  	Percentage

	 	 	 Milestone

	  	Amount

	 Fourth
	  	10	%	 	 After receipt of documentation of 45 % accrual (28 patients) for Phase II portion of study and all reported SAE’s (Fax copy of Medwatch
forms not previously submitted)
	  	$	37,200
				
	 Fifth
	  	15	%	 	 After receipt of documentation of 100% accrual (62 patients)* for Phase II portion of study and all reported SAE’s (Fax copy of Medwatch
forms not previously submitted)
	  	$	55,800
				
	 Final
	  	25	%	 	 After receipt and review of Final Study Report or Manuscript by Aventis
	  	$	93,000
	 	  	 	 	 	 	  	
	

	 Total
	  	100	%	 	 	  	$	372,000
	 	  	 	 	 	 	  	 	(62 pts. @ $6,000.00/pt.)
	 	  	 	 	 	 	  	
	

	*	Payment based on actual number of patients accrued to study. 

  

 Page 1 of 1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}]]